49. 全身性エリテマトーデス Systemic lupus erythematosus Clinical trials / Disease details
臨床試験数 : 993 / 薬物数 : 702 - (DrugBank : 184) / 標的遺伝子数 : 116 - 標的パスウェイ数 : 200
Showing 1 to 6 of 6 diseases
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR-INC-17011497 | 2017-05-25 | 2017-05-26 | Canceled by the investigator The efficacy and safety of metformin hydrochloride combined with atorvastatin in the treatment of moderate to severe activity systemic lupus erythematosus Canceled by the investigator The efficacy and safety of metformin hydrochloride combined with atorva ... | The efficacy and safety of metformin hydrochloride combined with atorvastatin in the treatment of moderate to severe activity systemic lupus erythematosus The efficacy and safety of metformin hydrochloride combined with atorvastatinin the treatment of mod ... | moderate to severe active systemic lupus erythematosus | Immunomodulation combined with traditional DMARDS treatment group:Immunomodulation combined with traditional DMARDS group: On the basis of glucocorticoid and traditional DMARDS treatment, metformin hydrochloride tablets 250mg, 3 times / day, oral; atorvastatin tablets 10mg, 1 times / day; in the first 4 weeks , 12 weeks and 24 weeks to assess the SELSNA-SLEDAI score table,traditional DMARDS treatment group:Traditional DMARDS treatment group: the use of glucocorticoid and traditional DMARDS treatment. The SELSNA-SLEDAI score table, BILAG worksheet, SLE damage index score were assessed at week 4, week 12 and week 24, and serum Th17, Treg and Th17 / Treg ratios were measured.; Immunomodulation combined with traditional DMARDS treatment group:Immunomodulation combined with tra ... | The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Te ... | NULL | Pending | Both | Immunomodulation combined with traditional DMARDS treatment group:60;traditional DMARDS treatment group:60; | China | |||
| 2 | ChiCTR-INR-17011495 | 2017-05-25 | 2017-05-26 | Canceled by the investigator The efficacy and safety of metformin hydrochloride combined with atorvastatin in the treatment of primary mild to moderate systemic sy Canceled by the investigator The efficacy and safety of metformin hydrochloride combined with atorva ... | The efficacy and safety of metformin hydrochloride combined with atorvastatin in the treatment of primary mild to moderate systemic systemic lupus erythematosus The efficacy and safety of metformin hydrochloride combined with atorvastatinin the treatment of pri ... | Primary mild to moderate systemic systemic lupus erythematosus | Immunomodulatory treatment group:The level of SELSNA-SLEDAI was evaluated at week 4, week 12 and week 24, the BILAG table, the SLE lesion index, and the SLE damage index were measured at 4 weeks, 12 weeks and 24 weeks. The levels of Th17, Treg and Th17 / Treg were measured.;Leflunomide treatment group:Leflunomide tablets 10m, 1 times / day, orally. The SELSNA-SLEDAI score table, BILAG worksheet, SLE damage index score were assessed at week 4, week 12 and week 24, and serum Th17, Treg and Th17 / Treg ratios were measured.;Immunomodulatory treatment group and Leflunomide treatment group :0 weeks to give prednisone acetate tablets 0.5-1mg / kg.d (or patients can choose to take the same dose of methylprednisolone tablets), 4 weeks after the beginning of the dose by 2 weeks to reduce the regular dose of 10% Reduction to prednisone acetate tablets 10mg / day to maintain.;Immunomodulatory treatment group and Leflunomide treatment group:All patients without contraindications plus hydroxychloroquine tablets 0.2,2 / day, orally; and according to the condition plus calcium (800-1200mg / day), vitamin D (200-800IU / day) and other treatment.; Immunomodulatory treatment group:The level of SELSNA-SLEDAI was evaluated at week 4, week 12 and wee ... | The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Te ... | NULL | Recruiting | Both | Immunomodulatory treatment group:15;Leflunomide treatment group:15;Immunomodulatory treatment group and Leflunomide treatment group :30;Immunomodulatory treatment group and Leflunomide treatment group:30; | China | |||
| 3 | NCT00519363 (ClinicalTrials.gov) | September 2007 | 20/8/2007 | Statins and Lupus: Effects of Statins on Clinical Lupus Parameters, Serological Markers and Toll-like Receptors Statins and Lupus: Effects of Statins on Clinical Lupus Parameters, Serological Markers and Toll-lik ... | Statins and Lupus: Effects of Statins on Clinical Lupus Parameters, Serological Markers and Toll-like Receptors. Statins and Lupus: Effects of Statins on Clinical Lupus Parameters, Serological Markers and Toll-lik ... | Systemic Lupus Erythematosus | Drug: atorvastatin | The Center for Rheumatic Disease, Allergy, & Immunology | Saint Luke's Health System | Completed | 18 Years | 60 Years | Female | 15 | Phase 1/Phase 2 | United States |
| 4 | NCT00432354 (ClinicalTrials.gov) | March 2007 | 6/2/2007 | An Open Labeled Pilot Study of Atorvastatin in Systemic Lupus Erythematosus | Systemic Lupus Erythematosus | Drug: atorvastatin | Buddhist Tzu Chi General Hospital | Pfizer | Recruiting | 16 Years | 80 Years | Both | 40 | Phase 2/Phase 3 | Taiwan | |
| 5 | NCT00412841 (ClinicalTrials.gov) | November 2002 | 18/12/2006 | Atorvastatin to Prevent Avascular Necrosis of Bone in Steroid Treated Exacerbated Systemic Lupus Erythematosus Atorvastatinto Prevent Avascular Necrosis of Bone in Steroid Treated Exacerbated Systemic Lupus Eryt ... | AVN Prevention With Lipitor in Lupus Erythematosus APLLE Trial | Avascular Necrosis | Drug: Atorvastatin;Procedure: MRI, Venipuncture;Drug: Placebo | NYU Langone Health | NULL | Terminated | 18 Years | 75 Years | Female | 43 | Phase 2 | United States |
| 6 | NCT00120887 (ClinicalTrials.gov) | April 2002 | 12/7/2005 | Lupus Atherosclerosis Prevention Study | Lupus Atherosclerosis Prevention Study | Systemic Lupus Erythematosus | Drug: Atorvastatin | Johns Hopkins University | Alliance for Lupus Research | Completed | 18 Years | N/A | Both | 200 | Phase 4 | United States |